Products with Immunomodulators bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN4128 | Phloretin |
| Phloretin may potentially be an immunomodulator by impairing the activation and function of DCs, it is effective in preventing estrogen deficiency-induced osteoclastogenic resorption. Phloretin has antimicrobial activity against the Gram negative bacteria Salmonella typhimurium ATCC 13311. It has a wide spectrum of targets including ASK-1-MAPK, Smac, capase. | |
| BCN4315 | Quassin |
| 1. Quassin exhibits P. falciparum inhibitory activity (IC50=0.06 micro g/ml, 0.15 micro M). 2. Quassin can significantly increase red blood cell count, pack cell volume and haemoglobin concentration, suggests that it possesses anti-anaemic property. 3. Quassin has female anti-fertility properties, possibly acting via inhibition of estrogen secretion. 4. Quassin alters the immunological patterns of murine macrophages through generation of nitric oxide to exert antileishmanial activity. | |
| BCN4385 | Rutaecarpine |
| Rutaecarpine is an inhibitor of COX-2 with an IC50 value of 0.28 μM, and is also a potent inhibitor of CYP1A2. Rutaecarpine has anti-atherosclerosis, immunosuppressive, anti-inflammatory, gastroprotective, vasorelaxing, antihypertensive and anti-platelet effects. Rutaecarpine has positive inotropic and chronotropic effects on the guinea-pig isolated right atria, possible involvement of vanilloid receptors. Rutaecarpine may be useful in the prevention of ultraviolet A-induced photoaging, it inhibits ultraviolet A-induced reactive oxygen species generation, resulting in the enhanced expression of matrix metalloproteinase (MMP)-2 and MMP-9 in human skin cells. | |
| BCN4390 | Eriocalyxin B |
| 1. Eriocalyxin B is a potent NF-kappaB inhibitor, can inhibit the NF-kappaB transcriptional activity but not that of cAMP response element-binding protein. 2. Eriocalyxin B reversibly interfer with the binding of p65 and p50 subunits to the DNA in a noncompetitive manner. 3. Eriocalyxin B exerts potent antiinflammatory effects through selective modulation of pathogenic Th1 and Th17 cells by targeting critical signaling pathways. 4. Eriocalyxin B inhibits proliferation and induces apoptosis through downregulation of Bcl-2 and activation of caspase-3 in human bladder cancer cells. 5. Eriocalyxin B induces apoptosis and cell cycle arrest in pancreatic adenocarcinoma cells through caspase- and p53-dependent pathways, should be considered a candidate for pancreatic cancer treatment. 6. Eriocalyxin B is a specific inhibitor of STAT3, it directly targets STAT3 through a covalent linkage to inhibit the phosphorylation and activation of STAT3 and induces apoptosis of STAT3-dependent tumor cells. | |
| BCN4400 | 2-Methoxystypandrone |
| 1. 2-Methoxystypandrone displays an immunomodulatory effect in a cellular model. 2. 2-Methoxystypandrone specifically inhibits JAK and IKKβ kinase activities. 3. 2-Methoxystypandrone blocks inflammatory responses by impairing NF-κB signaling to limit the inflammation and oxidative stress for preservation of BBB integrity. 4. 2-Methoxystypandrone concomitantly promotes neurodevelopmental protein expression and endogenous neurogenesis through inactivation of GSK3β to enhance β-catenin signaling for upexpression of neuroprotective genes and proteins. 5. 2-Methoxystypandrone has anti-osteoclastogenic effect, could reflect the block of RANKL-induced association of TRAF6-TAK1 complexes with consequent decrease of IkappaB-mediated NF-kappaB and mitogen-activated protein kinases-mediated c-Fos activation pathways and suppression of NFATc1 and other gene expression, essential for bone resorption. | |
